{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.73","value":"83.74"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"To determine the maximum concentration of Artesunate (AS) (Cmax) following five consecutive days of self-administration of 200mg Artesunate vaginal inserts (pessaries) among healthy women.\n\nMean artesunate Cmax (ng/ml) value will be submitted.","dispersionType":"Standard Deviation","groups":[{"description":"Artesunate vaginal inserts/pessaries are used as a treatment for cervical precancerous lesions.\n\nArtesunate pessary: Subjects will use the study pessaries, placed in the vagina every day for 5 consecutive days.\n\nblood draws for pharmacokinetics of the study drug: On day 5, all participants will have their blood draws before they use the pessary, and at 15 min, 30 mins, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after inserting the pessary. Blood samples will be tested for the pharmacokinetics of the study drug.","id":"OG000","title":"Artesunate Vaginal Inserts/ Pessaries"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Day 5","title":"To Determine the Maximum Concentration of Artesunate (AS)","type":"SECONDARY","unitOfMeasure":"ng/mL"}